Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon May 05, 2024 5:39pm
146 Views
Post# 36024098

RE:It’s Sunday, week review & look ahead time again

RE:It’s Sunday, week review & look ahead time again"No doubt in my mind what so ever, the likes of Roche, & Pfizer, have teams of lawyers dedicated to internatonal trade".

that may be so, but AN has exclusive rights to pela for any approved treatment using pela in the exclusive territory which was defined in the agreement.  that territory includes prc, hong kong, macau, republic of singapore, south korea, and taiwan.  collectively, those countries account for a little over 18% of the world population.

if oncy is taken out by the likes of roche or pfizer, or anyone else for that matter, they will get the same royalties that oncy negotiated for any sales in that exclusive territory.

that won't be chicken feed by any means, but it also won't be the whole ball of wax. the royalty percentage and specifics of those payments were blocked out the in agreement.

AND, the fda meeting is within 75 days, but the answer requesting a type c meeting is within 21 days.

possibly the corporate update/news hinted at could be about the fda's response to a type c meeting.
<< Previous
Bullboard Posts
Next >>